DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
企業コードDXCM
会社名Dexcom Inc
上場日Apr 14, 2005
設立日1999
最高経営責任者「CEO」Mr. Kevin R. Sayer
従業員数10300
証券種類Ordinary Share
決算期末Apr 14
本社所在地6340 Sequence Dr
都市SAN DIEGO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号92121
電話番号18582000200
ウェブサイトhttps://www.dexcom.com/
企業コードDXCM
上場日Apr 14, 2005
設立日1999
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし